Peptide Library

GLP-1 receptor agonist with extensive Phase 3 trial data for type 2 diabetes and chronic weight management. Prescription-only in most jurisdictions.

Dual GIP / GLP-1 receptor agonist with strong Phase 3 evidence in type 2 diabetes (SURPASS) and obesity (SURMOUNT).

Eli Lilly's triple agonist (GLP-1 / GIP / glucagon receptor). Currently the most potent weight-management investigational drug — Phase 2 trials reported ~24% body weight reduction at the highest dose. Phase 3 TRIUMPH program ongoing. Not yet FDA-approved.

Daily GLP-1 receptor agonist (Saxenda/Victoza). FDA-approved for chronic weight management and type 2 diabetes. Older sibling of semaglutide with smaller weight-loss effect size.

Novo Nordisk's once-weekly combination of cagrilintide (an amylin analog) and semaglutide. Designed to combine appetite suppression (semaglutide) with satiety + meal-size regulation (cagrilintide). REDEFINE-1 Phase 3 showed ~22.7% weight loss at 68 weeks — strong but below pre-trial expectations.

Eli Lilly's once-daily ORAL non-peptide GLP-1 receptor agonist (LY3502970). The first oral small-molecule GLP-1 with no food/water restrictions (unlike Rybelsus). Phase 3 ACHIEVE program for diabetes and ATTAIN for obesity both ongoing.

Melanocortin receptor agonist (Vyleesi) FDA-approved for hypoactive sexual desire disorder in premenopausal women. Acts on central pathways, not peripheral hormones.

Immunomodulatory peptide approved in some countries (e.g., for hepatitis B). Studied in immune modulation contexts.

GHRH analog (Egrifta) FDA-approved for HIV-associated lipodystrophy. Studied for visceral adiposity reduction outside that indication.

Boehringer Ingelheim / Zealand Pharma dual GLP-1 / glucagon receptor agonist (BI 456906). Strong Phase 2 obesity + MASH (liver) data. Phase 3 SYNCHRONIZE program ongoing across weight management, T2D, and liver disease indications.

Copper tripeptide studied in dermatology for skin remodeling and wound contexts. Topical formulations are widely used in cosmetics.

GHRH analog (first 29 amino acids of human GHRH). Stimulates endogenous growth hormone release. Approved for pediatric GH deficiency, widely used off-label in adults.

A pentadecapeptide derived from a sequence in human gastric juice. Most existing data is preclinical (animal models), exploring tissue repair, gut barrier, and tendon healing.

Growth-hormone secretagogue combination studied for stimulating endogenous GH pulses in research contexts.

Stealth BioTherapeutics' mitochondria-targeted tetrapeptide. Binds cardiolipin in the inner mitochondrial membrane and improves electron transport chain efficiency. Multiple Phase 3 trials in genetic mitochondrial diseases (Barth syndrome, primary mitochondrial myopathy) with mixed regulatory outcomes.

Mixture of low-molecular-weight peptides and free amino acids derived from porcine brain tissue (NOT a single defined peptide — a complex bioactive mixture). Approved in many European, Asian, and Latin American countries for stroke recovery, traumatic brain injury, and Alzheimer's disease. NOT FDA-approved in the US.

Coenzyme essential for cellular energy production and DNA repair (NOT a peptide — it's a nucleotide). Available as IV infusion, intranasal, and oral precursors (NR, NMN). Heavily discussed in longevity communities. Direct NAD+ supplementation has weak human RCT support; precursors have somewhat better data.

Synthetic hexapeptide (Glu-Glu-Met-Gln-Arg-Arg) marketed as a topical 'botox alternative.' Theoretically interferes with SNARE complex formation, reducing neurotransmitter release at neuromuscular junctions. Topical formulations are widely sold in cosmetics. Effect size is modest at best in published trials.

Synthetic fragment related to thymosin beta-4. Investigated in animal studies for cellular migration and tissue remodeling.

Heptapeptide analog of ACTH(4-10) studied in Russia for cognitive and neuroprotective effects after stroke.

Neuropeptide encoded by the KISS1 gene. Master regulator of the hypothalamic-pituitary-gonadal axis — stimulates GnRH release and downstream LH/FSH/sex-hormone production. Studied as a diagnostic and therapeutic agent for hypogonadism, infertility, and sexual function. Not FDA-approved.

Tetrapeptide studied primarily in Russian gerontology research for telomerase modulation and pineal function.

Growth Hormone Releasing Peptide-2. Synthetic hexapeptide ghrelin-receptor agonist. Stimulates GH release potently and consistently. Studied since the 1990s; approved in some Asian markets for diagnostic GH stimulation, NOT for therapeutic use in the US.

Synthetic hexapeptide growth-hormone secretagogue developed in the 1990s. Stimulates GH release potently in short-term human studies. Concerns about tachyphylaxis (tolerance) with chronic use have limited clinical development.

Synthetic analog of a fragment of human tuftsin, studied in Russia for anxiolytic and nootropic effects.

Insulin-like Growth Factor 1, Long R3 variant — an analog of human IGF-1 with extended half-life (~20-30 hours vs. ~12 minutes for native IGF-1). Used in research; widely (and controversially) discussed in performance-enhancement communities. NOT FDA-approved for human use; the only approved IGF-1 product is mecasermin (native sequence).

Modified fragment (amino acids 176-191) of the C-terminus of human growth hormone. Originally developed by Metabolic Pharmaceuticals as an anti-obesity agent. Failed to meet Phase 2 primary endpoints for weight loss. Repurposed as a research / supplement-market compound; in some jurisdictions classified as a food supplement.

Protein that binds and inhibits members of the TGF-β superfamily, most notably myostatin. Myostatin inhibition increases muscle mass in animals and in rare human genetic conditions (myostatin-deficient individuals). Heavy biohacking / bodybuilding interest. Limited human-trial data for any indication.

Mitochondrial-derived peptide encoded in the 12S rRNA. Preclinical data on insulin sensitivity, exercise capacity, and metabolic health. No FDA approval. Human data limited to small studies.

Splice variant of IGF-1 (specifically IGF-1Ec) produced locally in muscle in response to mechanical loading. Theorized to drive satellite-cell activation and muscle hypertrophy. Heavy bodybuilding-community interest. Limited human clinical-trial evidence. NOT FDA-approved.

Human cathelicidin antimicrobial peptide. Endogenous component of innate immunity with broad-spectrum antimicrobial, immunomodulatory, and wound-healing activity. Researched as a topical and systemic therapeutic across multiple indications; no FDA-approved formulation yet.

Tripeptide derivative of α-MSH studied in animal models of intestinal and skin inflammation.

Synthetic analog of α-melanocyte-stimulating hormone (α-MSH). Binds melanocortin receptors (notably MC1R for tanning and MC4R for sexual function). Originally researched for therapeutic skin pigmentation; abandoned in clinical development. Sold heavily as a grey-market 'tanning peptide.' Significant safety concerns — Class A action by some regulators.

Synthetic peptide corresponding to amino acids 176-191 of human growth hormone. Stripped of growth-promoting and glucose-modulating effects (theoretically). Originally developed under the AOD-9604 program (see related entry). Marketed as a 'pure lipolytic' but human-trial evidence for clinically meaningful weight loss is weak.

Delta sleep-inducing peptide originally isolated in studies of EEG slow-wave activity. Modern human data is sparse.

Synthetic peptidomimetic derived from angiotensin IV. Strong preclinical evidence for synaptogenesis (promoting new synapse formation) — described in animal studies as orders of magnitude more potent than BDNF in some assays. Of intense biohacking interest. NO human clinical trial data published.

Small-molecule NNMT inhibitor (NOT a peptide — it's a quinoline derivative). NNMT (nicotinamide N-methyltransferase) is upregulated in obese white adipose tissue. Preclinical studies show 5-Amino-1MQ reduces adipocyte size and improves metabolic markers in obese mice. No human RCTs. Sold as a research chemical.